Guangxi Liuzhou Pharm Co Ltd (603368) — Working Capital to Net Assets Ratio
Guangxi Liuzhou Pharm Co Ltd (603368) has a Working Capital to Net Assets ratio of 87.2% as of September 2025. Working capital of CN¥7.10 Billion (current assets of CN¥18.25 Billion minus current liabilities of CN¥11.16 Billion) is measured against net assets of CN¥8.14 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Guangxi Liuzhou Pharm Co Ltd (603368) balance sheet quality index to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Guangxi Liuzhou Pharm Co Ltd Working Capital to Net Assets (2011–2024)
This chart shows how Guangxi Liuzhou Pharm Co Ltd's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2011 to 2024. As of September 2025, the ratio stands at 87.2%, reflecting working capital of CN¥7.10 Billion against net assets of CN¥8.14 Billion CNY. Check 603368 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Guangxi Liuzhou Pharm Co Ltd (2011–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Guangxi Liuzhou Pharm Co Ltd from 2011 to 2024, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Guangxi Liuzhou Pharm Co Ltd stock valuation.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 85.1% | CN¥6.76 Billion | CN¥7.94 Billion | CN¥18.61 Billion | CN¥11.86 Billion | ▲ +4.4 pp |
| 2023 | 80.7% | CN¥5.70 Billion | CN¥7.06 Billion | CN¥17.32 Billion | CN¥11.61 Billion | ▼ -2.5 pp |
| 2022 | 83.2% | CN¥5.30 Billion | CN¥6.37 Billion | CN¥16.13 Billion | CN¥10.83 Billion | ▲ +1.3 pp |
| 2021 | 82.0% | CN¥4.76 Billion | CN¥5.81 Billion | CN¥13.39 Billion | CN¥8.63 Billion | ▼ -2.1 pp |
| 2020 | 84.0% | CN¥4.57 Billion | CN¥5.44 Billion | CN¥12.79 Billion | CN¥8.21 Billion | ▲ +14.9 pp |
| 2019 | 69.2% | CN¥3.22 Billion | CN¥4.66 Billion | CN¥10.09 Billion | CN¥6.87 Billion | ▲ +0.1 pp |
| 2018 | 69.0% | CN¥2.79 Billion | CN¥4.05 Billion | CN¥8.03 Billion | CN¥5.23 Billion | ▼ -11.1 pp |
| 2017 | 80.1% | CN¥2.86 Billion | CN¥3.57 Billion | CN¥6.79 Billion | CN¥3.93 Billion | ▼ -3.8 pp |
| 2016 | 83.9% | CN¥2.72 Billion | CN¥3.24 Billion | CN¥5.70 Billion | CN¥2.98 Billion | ▲ +9.5 pp |
| 2015 | 74.4% | CN¥1.01 Billion | CN¥1.36 Billion | CN¥3.89 Billion | CN¥2.88 Billion | ▼ -13.1 pp |
| 2014 | 87.5% | CN¥1.03 Billion | CN¥1.17 Billion | CN¥3.46 Billion | CN¥2.44 Billion | ▲ +12.1 pp |
| 2013 | 75.4% | CN¥377.66 Million | CN¥501.00 Million | CN¥2.55 Billion | CN¥2.17 Billion | ▼ -10.5 pp |
| 2012 | 85.9% | CN¥325.19 Million | CN¥378.59 Million | CN¥1.96 Billion | CN¥1.63 Billion | ▼ -0.8 pp |
| 2011 | 86.7% | CN¥237.81 Million | CN¥274.23 Million | CN¥1.52 Billion | CN¥1.28 Billion | — |